Business Wire

NY-ALIGNED-DATA-CENTERS

25.8.2015 14:01:22 CEST | Business Wire | Pressemeddelelse

Del
Aligned Data Centers Introduces the First Pay-for-Use Data Center

Aligned Data Centers announced today that it will offer consumption-based pricing to enterprises, service providers and governments who require greater control of data center cost and faster time-to-market.

Most data centers are built to support static power requirements and fixed densities. Forecasting future IT demand is difficult and results in stranded power and space. Data center customers are forced to commit to long-term contracts for power they may never use, which limits their ability to control the capacity they need to meet the needs of their business. Companies are demanding more flexibility and speed in how they deploy and scale their data centers.

“The current approach to the data center needs to evolve to keep pace with changing IT needs”, said Jakob Carnemark, CEO for Aligned Data Centers. “Today, the cloud makes it possible to access compute and storage on-demand, scale quickly, and only pay for what you use. We are delivering the same approach to the data center and are able to help our clients cut their colocation contract commitments by up to 75%.”

Aligned Data Centers’ consumption-based pricing eliminates the risk in forecasting future IT demand and provides the flexibility and speed companies require to adjust data center capacity as their business needs change.

According to Gartner analyst Bob Gill, “a more transparent and usage-based model is sorely needed.”

Aligned Data Centers was formed by a group of industry veterans with more than 25 years of experience designing, engineering, building, and operating production data centers for some of the largest and most innovative Internet, telecommunications, and financial services organizations.

“We don’t believe in a tradeoff between reliability and cost,” said Paul Fox, former Executive Director IT Infrastructure at Morgan Stanley and current Director of Operations for Aligned Data Centers. “We are delivering enterprise grade data centers in a cost model that customers have been demanding for years.”

Construction is nearing completion on the company’s Plano, Texas data center . When finished, the 30 megawatt data center will enable Aligned Data Centers’ clients to deploy multiple power densities within the same row and scale from 1-25kW per rack. In addition, this multi-tenant data center will feature the latest in energy efficient infrastructure, which uses 85% less water than traditional air-cooled systems and allows Aligned Data Centers to guarantee its clients an industry leading Power Usage Effectiveness (PUE) of 1.15. “We are excited to offer our clients the flexibility and efficiency they need to run the next-generation of IT,” said Fox.

In addition to the Plano data center, the company has also started construction of a massive 550,000 square foot, 65 megawatt data center in Phoenix, Arizona.

“We have seen a tremendous amount of interest in our pay-for-use approach and are in advanced discussions with a number of large clients at both locations,” said Ron Kolber, Executive Vice President of Sales for Aligned Data Centers.

Aligned Data Centers is backed by New York based BlueMountain Capital Management . The company will be expanding its North American footprint to four other markets including California, Illinois, Virginia, and New Jersey.

About Aligned Data Centers
Aligned Data Centers, a division of Aligned Energy, is the first pay-for-use data center provider to offer consumption-based pricing for on-demand data center capacity to enterprises, service providers, and governments who require greater control of data center cost and faster time-to-market.

Aligned Data Centers’ evolved approach eliminates the need to forecast future IT demand and provides control over power and space consumption independently, so its clients waste less and can better align the data center to the needs of their business.

For more information on Aligned Data Centers, please visit aligneddatacenters.com

Contact:

For Aligned Data Centers
Jonathan Pappas, 617-981-2194
jpappas@solomonmccown.com

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye